I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China Life Science
Alibaba shareholders approve stock split that could boost shares ahead of reported Hong Kong IPO Technology
MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China Life Science
China News Weekly 118 – Huawei Led China Mainland Innovation in First Half, Registering 2,314 Patents Financial Service, Life Science, Mining, Technology